Pazopanib-associated remodeling of platelet-immune cell crosstalk and immune suppressive platelet-derived extracellular vesicles in metastatic RCC
Despite the small sample size and absence of functional experiments, our results suggest that Pazopanib promotes cytotoxic immune programs but, by six months, reprograms PLT-EVs towards different adhesion characteristics contributing to Treg and MDSC expansion while suppressing NK activity. PLT-EVs may influence the balance between immune activation and suppression during anti-angiogenic therapy, suggesting PLT-EVs as biomarkers and therapeutic targets in mRCC.
Authors
- Emma Di Carlo (ORCID: https://orcid.org/0000-0001-7778-1042)
- Agata Cova (ORCID: https://orcid.org/0000-0003-2117-0757)
- Eriomina Shahaj (ORCID: https://orcid.org/0000-0001-5428-0405)
- Martina Stroscia
- Elisa D’Angelo (ORCID: https://orcid.org/0000-0002-5954-0939)
- Elisabetta Vergani (ORCID: https://orcid.org/0000-0001-6689-4981)
- Elena Verzoni (ORCID: https://orcid.org/0000-0001-9756-6112)
- Stefano Bergamini
- Alessandro Mereu
- Jeannette Salsetta
- Veronica Huber
- Licia Rivoltini
- Gianpiero Lupoli
Institutions
- University of Chieti-Pescara (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- University College London (GB)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1696460
- Primary Topic
- Extracellular vesicles in disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Associazione Italiana per la Ricerca sul Cancro